Tonix Pharmaceuticals competitors

Ron Cohen, M.D., President and Chief Executive Officer, founded Acorda Therapeutics, Inc. in 1995. Previously he was a principal in the startup and an officer of Advanced Tissue Sciences, Inc., a biotechnology company engaged in the growth of human organ tissues for transplantation. Dr. Cohen received his B.A. with honors in Psychology from Princeton University, and his M.D. from the Columbia College of Physicians & Surgeons. He completed his residency in Internal Medicine at the University of Virginia Medical Center, and is Board Certified in Internal Medicine. Dr. Cohen is a member of the Executive Committee and Vice Chair of the Health Section of the Biotechnology Industry Organization (BIO), and serves on the Board of Directors of Dyax Corp. He previously served as Director and Chairman of the New York Biotechnology Association (NYBA). He also serves as a member the Columbia-Presbyterian Health Sciences Advisory Council and was awarded Columbia University’s Alumni Medal for Distinguished Service. Dr. Cohen was named NeuroInvestment’s (now called NeuroPerspective) CEO of the Year and was recognized by PharmaVoice Magazine as one of the 100 Most Inspirational People in the Biopharmaceutical Industry. He is a recipient of the Ernst & Young Entrepreneur of the Year Award for the New York Metropolitan Region and is an inductee of the National Spinal Cord Injury Association’s “Spinal Cord Injury Hall of Fame.” In 2010, Dr. Cohen was recognized by the New York Biotechnology Association as the NYBA “The Cure Starts Here” Business Leader of the Year.

John 'Chip' Scarlett is a Co-Founder at Covance and Board Member at CYTOMX THERAPEUTICS, INC. and is based in Menlo Park, California. He has worked as Board Member at GERON CORP, Board Member at Chiasma Inc, and Adjunct Assistant Professor of Medicine at Hospital of the University of Pennsylvania. John works or has worked as Various Positions at Mcneil Pharmaceuticals and Dir:Medical Research & Svcs at Mcneil Pharmaceuticals. He studied at University of Colorado Boulder between 1980 and 1982, University of Chicago - The Pritzker School of Medicine between 1973 and 1977, and Earlham College between 1969 and 1973.

Mark L. Baum is the founder and CEO of Imprimis Pharmaceuticals whose mission is to provide patients and physicians with innovative and affordable ophthalmic drugs in the ocular surgery, glaucoma, and dry eye disease markets. He is also a founder and board member of Eton Pharmaceuticals and Surface Pharmaceuticals, as well as a board member and chairman of the audit committee of Ideal Power. He was named by Ernst & Young LLP as the 2017 Entrepreneur of the Year™ in the life sciences category for the San Diego region. Prior to Imprimis, as the founder of TBLF, LLC, a private investment fund, He made more than 200 investments into more than 40 private and public companies. In 1999, He founded YesRx, an HIV-focused pharmacy business. He's advocacy for drug pricing and accessibility issues has been reflected as an Op-Ed contributor for the Wall Street Journal and through appearances on CBS, CNN, MSNBC, Fox Business, Bloomberg and Al Jazeera. He is a 1995 cum laude graduate of The University of Texas at Arlington and a 1997 graduate of California Western School of Law.

John L. Higgins has over 14 years of corporate development, financing, strategic planning, commercialization, and investment banking experience in the biopharmaceutical industry. He is the chief executive officer of [Ligand Pharmaceuticals](https://www.crunchbase.com/organization/ligand-pharmaceuticals#/entity), a biotechnology company that focuses on the discovery and early-stage development of pharmaceuticals for medical needs in the United States. Prior to joining Ligand, Higgins was the chief financial officer; and executive vice president of finance, administration, and corporate development at Connetics Corporation, a public specialty pharmaceutical company, until its acquisition by Stiefel Laboratories, Inc. in 2006. During his service period of nearly 10 years at Connetics, he played a key leadership role in numerous strategic initiatives, including major acquisitions, divestitures, multiple product and technology licensing transactions, and financings. Prior to joining Connetics, Higgins was the executive vice president of corporate development at BioCryst Pharmaceuticals, Inc. and was a member of the health care investment banking team at Dillon, Read & Company, Inc. He has served numerous public and private corporate boards and currently is a director at BioCryst Pharmaceuticals, Inc. where he serves as chairman of the audit committee. Higgins earned a bachelor’s degree in Economics from Colgate University.

Recognized leader with highly successful experience and expertise in transforming and restructuring public and private companies, establishing strong governance processes and operational discipline, resulting in operational improvements, significant revenue and enterprise value growth. During his career, Mr. Dodd has overseen the approval of over 10 NDAs, over 15 acquisitions/divestitures, in excess of $2.5 billion in financial transactions and, over $5 billion in incremental enterprise growth. expertise in General Management; Board Leadership; Community & Industry Leadership.Specialties: General Management & Board Leadership Life Sciences IndustryBusiness TransformationsM&A

Purpose-driven company and team builder with more than 25 years of life science industry experience including 15+ years as CEO, leading organizations from formation to strategic exit. Proven experience in raising equity and debt capital, and developing strategic plans that result in demonstrable commercial value. Strong track record of negotiating and managing corporate and academic partnerships that drive value-creation, developing effective and aligned executive and operational teams, and recruiting highly-experienced Board of Directors. • “Start to Finish” CEO with experience in all company phases from seed stage to multi-million revenue product commercialization to strategic exit.Responsibility-centered leader who builds cohesive and intellectually aligned executive teams held accountable for collective results. • Proven success in raising multiple rounds of equity and debt capital from venture capital investors, banks, and corporate partners. • Extremely effective in communicating, both internally and externally, the “why” behind an organization’s existence and basis for its success. • Source, negotiate, close, and manage value-creating partnerships with “brand name” academic, pharmaceutical, biotech, and technology companies. • Strong educational foundation and hands-on experience in developing and implementing strategic plans that create value in early and mid-stage stage organizations. • Reputation among board members and employees as a dedicated and inspirational leader with the ability to motivate and maintain teams throughout a company’s lifecycle.• Experience in developing and executing on business models in both rare disease diagnostics and rare disease therapeutics.

Mr. Allan Oberman G. is a Chief Executive Officer at SAGENT PHARMACEUTICALS INC. and is based in United States.